Oral surgery, oral medicine, oral pathology and oral radiology · 2013
Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Chuanxia, Xie Bing, Yang Yi, Lin Duanxian, Wang Caixia, Lin Mei, Ge Lin, Zhou Hongmei
Аннотация
OBJECTIVE: This study aimed to determine the efficacy and safety of intralesional betamethasone in erosive oral lichen planus and to evaluate relapse of erosion.
STUDY DESIGN: Patients were randomly assigned to the experimental group (1.4 mg intralesional betamethasone) or to the control group (8 mg intralesional triamcinolone acetonide), and they received injections once a week for 2 weeks. Erosive area and pain level were assessed on days 1, 7 ± 2, and 14 ± 2. If the lesion disappeared, any recurrence within the following 3 months was recorded.
RESULTS: Twenty-nine participants in the experimental group and 30 in the control group completed the protocol. Healed percentage was higher with betamethasone (93.1%) than with triamcinolone (66.7%; P = .02), and final reduction in erosion area was greater in the experimental group (21.276 ± 21.064 mm(2)) than in the control group (11.5 ± 12.95 mm(2); P = .02). Reduction in pain level did not differ between groups. The proportion of participants with recurrent erosions was significantly lower in the experimental group (14.8%) than in the control group (45%; P = .04).
CONCLUSIONS: Intralesional betamethasone may be used in the topical treatment of erosive oral lichen planus.
STUDY DESIGN: Patients were randomly assigned to the experimental group (1.4 mg intralesional betamethasone) or to the control group (8 mg intralesional triamcinolone acetonide), and they received injections once a week for 2 weeks. Erosive area and pain level were assessed on days 1, 7 ± 2, and 14 ± 2. If the lesion disappeared, any recurrence within the following 3 months was recorded.
RESULTS: Twenty-nine participants in the experimental group and 30 in the control group completed the protocol. Healed percentage was higher with betamethasone (93.1%) than with triamcinolone (66.7%; P = .02), and final reduction in erosion area was greater in the experimental group (21.276 ± 21.064 mm(2)) than in the control group (11.5 ± 12.95 mm(2); P = .02). Reduction in pain level did not differ between groups. The proportion of participants with recurrent erosions was significantly lower in the experimental group (14.8%) than in the control group (45%; P = .04).
CONCLUSIONS: Intralesional betamethasone may be used in the topical treatment of erosive oral lichen planus.